A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

NCT00001805 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

Breast Neoplasms
Colonic Neoplasms
Lung Neoplasms
Pancreatic Neoplasms
Stomach Neoplasms

Interventions

DRUG: Rituximab

Sponsor

National Cancer Institute (NCI)